Evidence map›Paper›PMID 30046358›Full record

ReviewTherapeutic advances in medical oncology2018

Use of cold-atmospheric plasma in oncology: a concise systematic review.

Antoine Dubuc, Paul Monsarrat, François Virard, Nofel Merbahi, Jean-Philippe Sarrette, Sara Laurencin-Dalicieux, Sarah Cousty

Abstract readReview
In one paragraph

Review in Therapeutic advances in medical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Targeting proteostasis pathways for cancer therapy.Journal of pharmaceutical analysis · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antoine DubucDental Faculty, Paul Sabatier University, 3 Chemin des Maraîchers, Toulouse 31000, CHU Toulouse, France.ORCID https://orcid.org/0000-0002-3927-6165
Paul MonsarratDental Faculty, Paul Sabatier University, CHU Toulouse, France UMR STROMALab, Université Paul Sabatier, Toulouse, France.
François VirardCentre de Recherche en Cancérologie de Lyon, Université Lyon, Lyon, France.
Nofel MerbahiLAPLACE, UMR CNRS 5213, Université Paul Sabatier of Toulouse, France.
Jean-Philippe SarretteLAPLACE, UMR CNRS 5213, Université Paul Sabatier of Toulouse, France.
Sara Laurencin-DalicieuxDental Faculty, Paul Sabatier University, CHU Toulouse, France INSERM U1043, Université Toulouse, Toulouse, France.
Sarah CoustyDental Faculty, Paul Sabatier University, CHU Toulouse, France Lapace F-31062, Université de Toulouse, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCold-atmospheric plasma (CAP) is an ionized gas produced at an atmospheric pressure. The aim of this systematic review is to map the use of CAP in oncology and the implemented methodologies (cell targets, physical parameters, direct or indirect therapies).

methodsPubMed, the International Clinical Trials Registry Platform and Google Scholar were explored until 31 December 2017 for studies regarding the use of plasma treatment in oncology (

results190 original articles were included. Plasma jets are the most-used production systems (72.1%). Helium alone was the most-used gas (35.8%), followed by air (26.3%) and argon (22.1%). Studies were mostly

conclusionsThis study highlights the multiplicity of means of production and clinical applications of the CAP in oncology. While some devices may be used directly at the bedside, others open the way for the development of new pharmaceutical products that could be generated at an industrial scale. However, its clinical use strongly needs the development of standardized reliable protocols, to determine the more efficient type of plasma for each type of cancer, and its combination with conventional treatments.

Indexed as

neoplasmsnonthermal atmospheric pressure plasmaoncologyplasma jetreview

Identifiers

PMID30046358
PMCPMC6055243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.